Not very, according to the REACT Study conducted by the Imperial College London. The study was predicated on the importance of COX-2 in driving inflammation that contributes to tumorigenesis. The thinking was that administering celecoxib (Celebrex), a COX-2 inhibitor, could reduce breast cancer progression, as suggested in smaller observational trials. Continue reading
Tag Archives: Ilaris
CANTOS trial of canakinumab demonstrates that inflammation is a lung cancer promoter
Cells need to accumulate multiple mutations in order to induce the 10 hallmarks of cancer: Continue reading